Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomerieux SA Confirms FY 2013 Revenue Guidance and Issues FY 2013 Operating Profit Guidance in Line with Analysts' Estimates


Tuesday, 3 Sep 2013 12:17pm EDT 

Biomerieux SA announced that it has confirmed its fiscal year 2013 guidance of sales growth between 3% and 5%. For fiscal year 2012, the Company reported a revenue of EUR 1,570.00 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report for fiscal year 2013 a revenue of EUR 1,607.79 million, what reflects a 2.41% growth. The Company also announces that it expects to report for fiscal year 2013 an operating income before non-recurring items of between EUR 255 million and EUR 270 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report for fiscal year 2013 an operating profit of 296 million. 

Company Quote

77.75
0.25 +0.32%
30 Jul 2014